Study of Multiple Myeloma Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2

Phase 3 Terminated 5 enrolled University of Arkansas

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study is being done to find out if the combination of VelcadeTM with melphalan and dexamethasone (VMD) will be as effective, or even more effective as it is in combination with thalidomide and dexamethasone (VTD).

Timeline

Start: 2006-08
Primary completion: 2008-07
Completion: 2008-07

Publications

Usmani SZ, Sexton R, Hoering A, Heuck CJ, Nair B, Waheed S, Al Sayed Y, Chauhan N, Ahmad N, Atrash S, Petty N, van Rhee F, Crowley J, Barlogie B. Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance. Blood. 2012 Aug 23;120(8):1597-600. doi: 10.1182/blood-2012-04-421883. Epub 2012 Jun 6.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Melphalan	Small molecule	—	—
Subject	Thalidomide	Other / unclassified	—	Oral
Background	Bortezomib	Small molecule	—	Intravenous
Background	Dexamethasone	Small molecule	—	—

Study of Multiple Myeloma Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2

Summary

Timeline

Publications

Drugs

Indications